BriaCell Therapeutics Corp. (TSX:BCT)

BriaCell Therapeutics Ratios and Metrics

Market cap in millions CAD. Fiscal year is August - July.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 4, 2026	Jul 31, 2024	Jul 31, 2023	Jul 31, 2022	Jul 31, 2021	Jul 31, 2020
Market Cap	40	19	145	137	107	7
Market Cap Growth	100.57%	-87.15%	6.21%	27.16%	1428.30%	-46.84%
Enterprise Value	24.74	17.07	116.09	80.53	29.18	7.56
PE Ratio	-	-2.57	-5.11	-3.78	-1.68	-1.26
PB Ratio	3.04	-5.72	-28.09	9.67	2.84	-1.43
P/TBV Ratio	0.53	-7.11	-36.22	12.57	1.05	-1.89
P/FCF Ratio	-	-0.55	-4.47	-8.00	-10.14	-4.06
P/OCF Ratio	-	-0.57	-4.47	-8.00	-10.14	-4.06
EV/EBITDA Ratio	-	-0.38	-3.65	-3.85	-3.06	-1.41
EV/EBIT Ratio	-	-0.37	-3.65	-3.85	-3.06	-1.40
EV/FCF Ratio	-	-0.51	-3.57	-4.71	-2.75	-4.36
Debt / Equity Ratio	-	0	0	0	0.00	-0.11
Debt / EBITDA Ratio	-	-	-	-	0.00	-0.10
Debt / FCF Ratio	-	-	-	-	0.00	-0.32
Quick Ratio	3.42	0.49	14.96	43.64	102.88	0.01
Current Ratio	3.42	0.49	14.96	45.00	103.81	0.07
Return on Equity (ROE)	-440.17%	152.63%	-619.75%	-141.25%	-114.78%	191.77%
Return on Assets (ROA)	-234.48%	-201.78%	-66.74%	-30.39%	-23.82%	-814.79%
Return on Invested Capital (ROIC)	-1350.40%	-1053.18%	-989.19%	-3640.60%	-1844.83%	-710.25%
Return on Capital Employed (ROCE)	-373.81%	-280.40%	-69.47%	-30.85%	-25.82%	190.77%
Earnings Yield	-100.88%	-38.88%	-19.58%	-26.44%	-59.47%	-79.21%
FCF Yield	-	-180.26%	-22.38%	-12.50%	-9.86%	-24.62%
Buyback Yield / Dilution	-130.17%	-32.40%	-3.73%	3.67%	-83.15%	-22.40%

Updated Oct 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.